72 Participants Needed

Semaglutide for Cognitive Impairment in Depression

RB
Overseen ByRodrigo B. Mansur, MD, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Phase 2
Sponsor: University Health Network, Toronto
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial will test if semaglutide can improve thinking skills in overweight people with depression. Semaglutide is a medication that helps control blood sugar and might also help the brain work better. It is used for weight loss and blood sugar control, and has shown potential benefits for brain function.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've been treated with oral hypoglycemic agents or insulin in the past 4 weeks.

What data supports the effectiveness of the drug Semaglutide for cognitive impairment in depression?

Research suggests that Semaglutide may protect against Alzheimer's disease by enhancing autophagy (the body's way of cleaning out damaged cells) and inhibiting apoptosis (cell death), which could be relevant for cognitive impairment in depression.12345

Is semaglutide safe for humans?

Semaglutide, used in treatments like Rybelsus, Ozempic, and Wegovy, has been tested in people with type 2 diabetes and is generally considered safe. It has a similar safety profile to other drugs in its class and does not increase heart-related risks compared to a placebo.12678

How is the drug semaglutide unique for treating cognitive impairment in depression?

Semaglutide is unique because it is a glucagon-like peptide-1 (GLP-1) analogue that is typically used for diabetes and weight loss, but it may also protect against cognitive decline by enhancing autophagy (the body's way of cleaning out damaged cells) and inhibiting apoptosis (cell death). This mechanism is different from traditional antidepressants, which primarily focus on altering brain chemicals.59101112

Research Team

RB

Rodrigo B. Mansur, MD, PhD

Principal Investigator

University Health Network, Toronto

Eligibility Criteria

This trial is for adults aged 18-60 with major depressive disorder (MDD) who have cognitive issues and are overweight. Participants must perform below average on a specific cognitive test and not be severely depressed, drug-dependent, pregnant, or breastfeeding. They can't have certain mental health conditions or be taking diabetes medications.

Inclusion Criteria

My BMI is 25 or higher, indicating I am overweight.
I am between 18 and 60 years old and have been diagnosed with major depression.
Below-average (i.e. >1 SD below norm) performance in the Trail Making Test-B (TMTB)
See 1 more

Exclusion Criteria

I have used diabetes medication or insulin in the last 4 weeks.
I have a history of neurological disorders or illnesses that could affect my thinking.
I have been diagnosed with Alzheimer's, Mild Cognitive Impairment, or another form of dementia.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive semaglutide or placebo once daily, with dosage adjustments over 16 weeks

16 weeks
Regular visits for dosage adjustments and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Semaglutide
Trial OverviewThe study tests if semaglutide improves brain function in people with MDD. It's a comparison between semaglutide and a placebo (a substance with no active drug). Participants will receive either the real medication or placebo without knowing which one they're getting.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: SemaglutideExperimental Treatment1 Intervention
Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
Group II: PlaceboPlacebo Group1 Intervention
Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).

Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Ozempic for:
  • Type 2 diabetes
  • Cardiovascular disease
  • Obesity
🇺🇸
Approved in United States as Ozempic for:
  • Type 2 diabetes
  • Cardiovascular disease
  • Obesity
🇨🇦
Approved in Canada as Ozempic for:
  • Type 2 diabetes
  • Cardiovascular disease
  • Obesity
🇯🇵
Approved in Japan as Ozempic for:
  • Type 2 diabetes
  • Cardiovascular disease
  • Obesity
🇺🇸
Approved in United States as Wegovy for:
  • Obesity
🇺🇸
Approved in United States as Rybelsus for:
  • Type 2 diabetes

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+

Findings from Research

In a study of 20 patients with type 2 diabetes in Slovenia, oral semaglutide significantly reduced HbA1c levels and fasting plasma glucose, indicating its efficacy in improving glycaemic control.
Patients reported high satisfaction with the treatment, and while some experienced mild gastrointestinal side effects, the overall safety profile was considered good, suggesting that oral semaglutide is a promising option for diabetes management.
Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.Janić, M., Jovanović, M., Janež, A., et al.[2023]
Oral semaglutide, particularly at doses of 14 mg or flexibly dosed, significantly reduced HbA1c levels and body weight in patients with type 2 diabetes compared to other treatments, especially in those with higher baseline HbA1c levels.
The safety profile of oral semaglutide was comparable to that of other treatments, although it was associated with a higher incidence of gastrointestinal adverse events, which were consistent across different patient subgroups.
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.Aroda, VR., Bauer, R., Christiansen, E., et al.[2022]
In two phase III trials involving 2764 participants with overweight or obesity, semaglutide 2.4 mg once weekly significantly improved cardiometabolic risk factors, including reductions in waist circumference, blood pressure, and fasting glucose compared to placebo.
The benefits of semaglutide were not sustained after stopping the treatment, indicating that ongoing administration may be necessary to maintain improvements in health outcomes.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.Kosiborod, MN., Bhatta, M., Davies, M., et al.[2023]

References

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience. [2023]
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. [2022]
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. [2021]
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. [2023]
Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. [2021]
[Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)]. [2022]
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. [2022]
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. [2022]
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis. [2023]
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. [2022]
Case Report: Semaglutide-associated depression: a report of two cases. [2023]